Clinical trial

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

NCT00821964

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record imiquimod Normalized identity: imiquimodView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Abraxane Normalized identity: AbraxaneView linked drug · Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention laboratory biomarker analysis Find medicine records · Find other trials using this name

GENETIC · Unmapped registry intervention RNA analysis Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention immunoenzyme technique Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-12-01

PhasePHASE2

Conditions

Male Breast Cancerverified · MONDO: male breast carcinoma

Recurrent Breast Cancerunresolved

Skin Metastasesunresolved

Stage IV Breast Cancerunresolved

Interventions

imiquimodDRUG · verified · RxNorm: imiquimod

AbraxaneDRUG · verified · RxNorm: Abraxane

laboratory biomarker analysisOTHER

RNA analysisGENETIC

immunoenzyme techniqueOTHER

Sponsors & collaborators

University of Washingtonlead sponsor

National Cancer Institute (NCI)collaborator

Mapped research locations

SeattleWashington, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00821964 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.